Novo Nordisk And Our Core Strategy

How your returns can be even better than the performance of our top names.

Novo Nordisk's All-Time High 

As ZeroHedge reported today, shares of Novo Nordisk A/S ( NVO 0.00%↑ ) hit an all-time high after China approved the Danish company's anti-obesity drug, Wegovy. Novo Nordisk was a Portfolio Armor top name, and I personally own it. Its performance in my account illustrates two points I've made elsewhere recently: 

1. Portfolio Armor's top names generate strong performance. We've been posting the current top ten in our trading Substack since December, 2022, and so far we have 6-month returns for 52 top names cohorts. Our top names have returned 23.46%, on average, over the next 6 months, versus 12.82% for SPY. 

2. Your performance following our core strategy will likely be even better, because you will be letting your winners run (our core strategy is to buy equal dollar amounts of our top ten names, put trailing stops of 15%-20% on them, and then replace them with new top names when we get stopped out). In the 6 months after I bought NVO when it appeared in our top ten in April of 2023, NVO was up 17.01%. However, I never got stopped out of NVO, so I still own it. I am up 80.17% on NVO so far.